ParenteralTopicalDosed ingredient Cosmetic cross-reference

Sodium Fluoride

CAS 7681-49-4

Sodium Fluoride (CAS 7681-49-4) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 2,352 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
2,352
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Sodium Fluoride
CAS Number
7681-49-4
UNII
8ZYQ1474W7
InChIKey
PUZPDOWCWNUUKD-UHFFFAOYSA-M
ChEMBL ID
CHEMBL1528
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientparenteraltopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1528 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE DrugCentral 21 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Cytokine release syndrome 53 120.853 10052015
Respiratory tract infection bacterial 25 107.963 10060693
Respiratory tract infection viral 26 91.823 10062106
Fibrin D dimer increased 23 64.354 10016581
Lymphoma 28 55.671 10025310
Respiratory tract infection 33 45.218 10062352
Somnambulism 15 37.015 10041347
Platelet count decreased 50 30.573 10035528
Eye infection 16 30.502 10015929
Myotonic dystrophy 5 26.685 10068871
Trifascicular block 5 24.559 10044644
Urethral injury 4 22.497 10046454
Pulmonary embolism 40 21.685 10037377
Myelodysplastic syndrome 17 20.382 10028533
Hypotension 67 20.337 10021097
Hepatitis B 10 18.146 10019731
Nightmare 15 17.943 10029412
Thrombocytopenia 48 17.249 10043554
Ototoxicity 7 17.15 10033109
Faeces soft 9 16.915 10074859
Hypoaesthesia eye 4 16.649 10020939

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
SODIUM FLUORIDE 9873 SU MTHSPL
Sodium Fluoride 9873 SU MTHSPL
sodium fluoride 9873 SU MTHSPL
sodium fluoride 9873 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Sodium Fluoride used for in pharmaceutical contexts?

Sodium Fluoride (CAS 7681-49-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Sodium Fluoride?

Sodium Fluoride has 2,352 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Cytokine release syndrome, Respiratory tract infection bacterial, Respiratory tract infection viral, Fibrin D dimer increased, Lymphoma. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Sodium Fluoride also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Sodium Fluoride with EU status "restricted".

What clinical phase is Sodium Fluoride in?

Sodium Fluoride is rendered with ChEMBL max phase 4 (approved).